Skip to content
10-Q

Quarterly Report

NewAmsterdam Pharma Company N.V. NAMS NAMSW

0001193125-25-265796

← back to feed
Filed
Nov 5, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Oct 31, 2025 113.39M sh
Shares Diluted Q3 2025 · Sep 30, 2025 119M sh
Shares Diluted Q3 2025 · Sep 30, 2025 117.9M sh
Shares Diluted Q3 2025 · Sep 30, 2024 94.75M sh
Shares Diluted Q3 2025 · Sep 30, 2024 92.67M sh
Capex Q3 2025 · Sep 30, 2025 $146K
Capex Q3 2025 · Sep 30, 2024 $669K
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$106.91M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$121.08M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $538.41M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $771.74M
Cash And Equivalents Q3 2025 · Sep 30, 2024 $422.73M
Stockholders Equity Q3 2025 · Sep 30, 2025 $728.07M
Stockholders Equity Q3 2025 · Jun 30, 2025 $778.5M
Stockholders Equity Q3 2025 · Mar 31, 2025 $777.36M
Stockholders Equity Q3 2025 · Dec 31, 2024 $757.5M
Stockholders Equity Q3 2025 · Sep 30, 2024 $378.86M
Stockholders Equity Q3 2025 · Jun 30, 2024 $387.44M
Stockholders Equity Q3 2025 · Mar 31, 2024 $411.8M
Stockholders Equity Q3 2025 · Dec 31, 2023 $288.39M
Current Liabilities Q3 2025 · Sep 30, 2025 $58.27M
Current Liabilities Q3 2025 · Dec 31, 2024 $106.92M
Total Liabilities Q3 2025 · Sep 30, 2025 $58.36M
Total Liabilities Q3 2025 · Dec 31, 2024 $107.12M
Current Assets Q3 2025 · Sep 30, 2025 $732.33M
Current Assets Q3 2025 · Dec 31, 2024 $863.41M
Total Assets Q3 2025 · Sep 30, 2025 $786.43M
Total Assets Q3 2025 · Dec 31, 2024 $864.62M
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.61
Eps Diluted Q3 2025 · Sep 30, 2025 −$1.09
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.18
Eps Diluted Q3 2025 · Sep 30, 2024 −$1.61
Eps Basic Q3 2025 · Sep 30, 2025 −$0.61
Eps Basic Q3 2025 · Sep 30, 2025 −$1.09
Eps Basic Q3 2025 · Sep 30, 2024 −$0.18
Eps Basic Q3 2025 · Sep 30, 2024 −$1.61
Sga Expense Q3 2025 · Sep 30, 2025 $24.52M
Sga Expense Q3 2025 · Sep 30, 2025 $78.94M
Sga Expense Q3 2025 · Sep 30, 2024 $18.41M
Sga Expense Q3 2025 · Sep 30, 2024 $49.34M
Rd Expense Q3 2025 · Sep 30, 2025 $30.97M
Rd Expense Q3 2025 · Sep 30, 2025 $103.24M
Rd Expense Q3 2025 · Sep 30, 2024 $35.7M
Rd Expense Q3 2025 · Sep 30, 2024 $116.51M
Net Income Q3 2025 · Sep 30, 2025 −$72.01M
Net Income Q3 2025 · Sep 30, 2025 −$128.9M
Net Income Q3 2025 · Sep 30, 2024 −$16.65M
Net Income Q3 2025 · Sep 30, 2024 −$149.42M
Operating Income Q3 2025 · Sep 30, 2025 −$55.14M
Operating Income Q3 2025 · Sep 30, 2025 −$159.7M
Operating Income Q3 2025 · Sep 30, 2024 −$25M
Operating Income Q3 2025 · Sep 30, 2024 −$133.06M
Revenue Q3 2025 · Sep 30, 2025 $348K
Revenue Q3 2025 · Sep 30, 2025 $22.47M
Revenue Q3 2025 · Sep 30, 2024 $29.11M
Revenue Q3 2025 · Sep 30, 2024 $32.79M